Literature DB >> 36051362

Primary CNS lymphoma in Immunocompetent patients: Appearances on Conventional and Advanced Imaging with Review of literature.

Anagha Joshi1, Sneha Deshpande1, Madhura Bayaskar1.   

Abstract

Primary central nervous system lymphoma (PCNSL) constitutes about 3% of all primary brain tumors and nearly 1 to 3% of all Non Hodgkin Lymphomas. In the recent years the incidence of primary CNS lymphoma is increasing in immunocompetent patients. As PCNSL are chemosensitive as well as radiosensitive, its early and accurate diagnosis is imperative for optimal management. Contrast enhanced Magnetic Resonance Imaging (MRI) is the recommended imaging modality for PCNSL; however, contrast enhanced Computed Tomography (CE-CT) is done in cases where MRI is contraindicated. Advanced imaging techniques like DWI (diffusion weighted imaging), MRS (MR Spectroscopy), MR perfusion, DTI (Diffusion tensor imaging) are important in diagnosis and help in its differentiation from other tumors. Copyright Journal of Radiology Case Reports.

Entities:  

Keywords:  Primary CNS lymphoma; advanced imaging techniques; computed tomography; immunocompetent; magnetic resonance imaging

Mesh:

Year:  2022        PMID: 36051362      PMCID: PMC9354935          DOI: 10.3941/jrcr.v16i7.4562

Source DB:  PubMed          Journal:  J Radiol Case Rep        ISSN: 1943-0922


  28 in total

1.  Differentiation of Primary Central Nervous System Lymphoma From Glioblastoma: Quantitative Analysis Using Arterial Spin Labeling and Diffusion Tensor Imaging.

Authors:  Ahmed Abdel Khalek Abdel Razek; Lamiaa El-Serougy; Mohamed Abdelsalam; Gada Gaballa; Mona Talaat
Journal:  World Neurosurg       Date:  2018-11-29       Impact factor: 2.104

Review 2.  Primary central nervous system lymphoma.

Authors:  Nimish A Mohile; Lauren E Abrey
Journal:  Neurol Clin       Date:  2007-11       Impact factor: 3.806

3.  Differentiating Primary Central Nervous System Lymphomas From Glioblastomas and Inflammatory Demyelinating Pseudotumor Using Relative Minimum Apparent Diffusion Coefficients.

Authors:  Jian-Bo Wen; Wei-Yuan Huang; Wei-Xing-Zi Xu; Gang Wu; Dao-Ying Geng; Bo Yin
Journal:  J Comput Assist Tomogr       Date:  2017 Nov/Dec       Impact factor: 1.826

4.  Primary central nervous system lymphoma: analysis of prognostic variables and patterns of treatment failure.

Authors:  J M Michalski; D M Garcia; E Kase; P W Grigsby; J R Simpson
Journal:  Radiology       Date:  1990-09       Impact factor: 11.105

5.  MRI findings of primary CNS lymphoma in 26 immunocompetent patients.

Authors:  Dong Zhang; Liang-Bo Hu; Tobias D Henning; Elisabeth M Ravarani; Li-Guang Zou; Xiao-Yuan Feng; Wen-Xian Wang; Li Wen
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

6.  Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients.

Authors:  A Coulon; F Lafitte; K Hoang-Xuan; N Martin-Duverneuil; K Mokhtari; J Blustajn; J Chiras
Journal:  Eur Radiol       Date:  2001-09-21       Impact factor: 5.315

7.  Differentiation of Enhancing Glioma and Primary Central Nervous System Lymphoma by Texture-Based Machine Learning.

Authors:  P Alcaide-Leon; P Dufort; A F Geraldo; L Alshafai; P J Maralani; J Spears; A Bharatha
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-27       Impact factor: 3.825

8.  Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics.

Authors:  Alexander C Guo; Thomas J Cummings; Rajesh C Dash; James M Provenzale
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

9.  Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy.

Authors:  T Thomas Zacharia; Meng Law; Thomas P Naidich; Norman E Leeds
Journal:  J Neuroimaging       Date:  2008-05-19       Impact factor: 2.486

10.  Comparison between Glioblastoma and Primary Central Nervous System Lymphoma Using MR Image-based Texture Analysis.

Authors:  Akira Kunimatsu; Natsuko Kunimatsu; Kouhei Kamiya; Takeyuki Watadani; Harushi Mori; Osamu Abe
Journal:  Magn Reson Med Sci       Date:  2017-06-22       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.